Arabic Arabic English English French French German German
dark

iCAD’s Xoft Brain IORT Demonstrates Significant Improvement in Overall Survival in Recurrent Glioblastoma According to Comparative Study

iCAD, Inc. today announced that encouraging results from a prospective two center comparative study evaluating the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of recurrent glioblastoma (GBM) Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Medtech Incubators and Accelerators: Where Are the Hubs for Medical Device Innovation?

Next Post

Organ transplants fell by a third worldwide during first wave of COVID-19 pandemic, new study presented at ESOT Congress 2021 shows

Related Posts
Total
0
Share